Unlike semaglutide, which activates only the GLP-1 receptor, or tirzepatide, which targets both GLP-1 and GIP, retatrutide engages three key metabolic receptors simultaneously: GLP-1 receptor curbs appetite, slows gastric emptying, and lowers blood sugar
Primary indication is diabetes management based on blood glucose criteria, not BMI
Fatigue has been reported as a side effect of retatrutide
Every formulation is manufactured to US-grade cGMP standards and third-party tested for purity and potency, thus meeting the high standards required by the UK market, while Zenith Nano technology remains exclusive to Vora Health UK
Decision timeline Timelines vary by goal, dose, baseline health, and consistency
Illustration by Leah Abucayan/CNN New potent drugs are reshaping obesity care, promising larger weight loss for some patients, but safety, access, and oversight remain urgent concerns